A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma-Reference-Cited by-同舟云学术

A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma

Published:2015-07-31 Issue:1 Volume:63 Page:39-46
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Mitchell Deanna¹²,Bergendahl Genevieve¹,Ferguson William³,Roberts William⁴,Higgins Timothy⁵,Ashikaga Takamaru⁶,DeSarno Mike⁶,Kaplan Joel⁷,Kraveka Jacqueline⁸,Eslin Don⁹,Werff Alyssa Vander¹,Hanna Gina K.¹⁰,Sholler Giselle L. Saulnier¹²

Affiliation:

1. Helen DeVos Children's Hospital; Grand Rapids Michigan

2. Michigan State University College of Human Medicine; Grand Rapids Michigan

3. Cardinal Glennon Children's Medical Center; Saint Louis University School of Medicine; Saint Louis Missouri

4. Rady Children's Hospital; University of California San Diego School of Medicine; San Diego California

5. Department of Radiology; University of Vermont Medical Center; Burlington Vermont

6. Medical Biostatistics and Biometry Facility; University of Vermont College of Medicine; Burlington Vermont

7. Levine Children's Hospital; Charlotte North Carolina

8. Medical University of South Carolina; Charleston South Carolina

9. Arnold Palmer Hospital for Children; Orlando Florida

10. Dana-Farber Cancer Institute; Boston Massachusetts

Funder

Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) (Cortice Biosciences)

Beat NB Foundation

Max's Ring of Fire

Meryl and Charles Witmer Foundation

Owen Moscone Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference31 articles.

1. Society AC . 2008

2. A population-based study of neuroblastoma incidence, survival, and mortality in North America;Bernstein;J Clin Oncol,1992

3. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment;Brodeur;J Clin Oncol,1993

4. Neuroblastoma: Biology, prognosis, and treatment;Park;Pediatr Clin North Am,2008

5. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution;Hartmann;Bone Marrow Transplant,1999

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biocompatible polymeric nanoparticles as carriers for anticancer phytochemicals;European Polymer Journal;2024-01

2. The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo;Cancer Chemotherapy and Pharmacology;2023-01-25

3. Strategies for the drug discovery and development of taxane anticancer therapeutics;Expert Opinion on Drug Discovery;2022-10-14

Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use

;International Journal of Nanomedicine;2020-11

5. Synthesis and Initial In Vivo Evaluations of [ 11 C]WX‐132‐18B, a Microtubule PET Imaging Agent;ChemistrySelect;2020-08-18